OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers
MWN-AI** Summary
OneMedNet Corporation, a leader in AI-ready Real-World Data (RWD) solutions, has entered a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology firm focusing on EEG-based digital biomarkers. Announced on February 24, 2026, this partnership is designed to advance research and development within neurology, psychiatry, and sleep domains.
The agreement represents a significant move for OneMedNet, contributing millions in recurring revenue through multi-year contracts. Following a swift negotiation process, data delivery is now in progress under a three-month project, highlighting Risorius’ urgency and confidence in OneMedNet's robust regulatory-grade data assets. The licensed content will include extensive electroencephalography (EEG) and polysomnography (PSG) data, enriched with longitudinal clinical context, critical for driving innovation in digital biomarkers.
Risorius' CEO Sangyoon Bae emphasized the strong alignment of OneMedNet's offerings with their needs, specifically citing the combination of curated high-fidelity data and a scalable licensing model essential for internal R&D and the development of their AI Co-Scientist platform. This platform aims to enhance workflows in CNS research, ultimately accelerating hypothesis testing and clinical study outcomes.
Aaron Green, CEO of OneMedNet, noted that this partnership showcases the growing demand for scalable, high-quality datasets pivotal for AI-driven innovations. This strategic move underlines OneMedNet's commitment to enriching the neuro and CNS verticals and its role as a trusted infrastructure partner in the AI landscape.
Both companies are poised to leverage this collaboration to enhance their technological capabilities and drive breakthroughs in healthcare. As the demand for advanced analytics and digital biomarkers in CNS research continues to rise, this alliance positions OneMedNet and Risorius at the forefront of innovation in neurotechnology.
MWN-AI** Analysis
The recent announcement from OneMedNet Corporation (Nasdaq: ONMD) regarding its strategic partnership with Risorius Co., Ltd. marks a pivotal moment not only for the companies involved but also for investors observing the growing intersection of artificial intelligence and healthcare. This partnership, focused on EEG and PSG data licensing, strengthens OneMedNet’s subscription revenue model while positioning it as a major player in the data space for neurotechnology research.
Investors should be aware of several key indicators from this partnership that underscore a favorable outlook for ONMD. The rapid execution of the agreement illustrates a strong market demand for high-quality real-world data (RWD), particularly in the Central Nervous System (CNS) space—a field projected to grow significantly due to ongoing advancements in neurotechnology. Risorius' selection of OneMedNet suggests a robust product-market fit that could lead to further collaborations and expansions in the pipeline.
OneMedNet's ability to provide regulatory-grade, AI-ready datasets caters to a burgeoning market of AI-native enterprises focusing on CNS conditions. As the healthcare industry increasingly relies on data analytics for clinical innovation, OneMedNet is positioned to benefit from a surge in demand for its services. The agreement is expected to yield millions in recurring revenue and reflects a commitment to long-term growth through subscription models.
However, it is essential for investors to remain vigilant. They should consider potential risks outlined in OneMedNet's forward-looking statements, including market competitiveness and technological advancement. The stock may be subject to volatility as OneMedNet navigates these challenges.
Overall, while there are inherent risks in the tech and healthcare sectors, the strategic partnership with Risorius is a significant bullish signal. Investors looking for companies that blend innovative technology with healthcare solutions may find ONMD an attractive addition to their portfolios.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep. This new relationship supports OneMedNet’s continued focus on expanding its base of subscription contracts, adding multi-year agreements that represent millions of dollars in incremental recurring revenue.
The agreement was executed in record time following the companies’ initial meeting, reflecting strong commercial alignment, clear product-market fit, and immediate value to the customer. Data delivery is now underway and will be continuously delivered over a three-month project under a licensing agreement, delivering diverse multimodal data at scale. The speed of execution underscores the value Risorius placed on OneMedNet’s regulatory-grade data assets and delivery model.
Under the agreement, Risorius has licensed access to large-scale electroencephalography (EEG) and polysomnography (PSG) waveform data paired with clinically meaningful context and longitudinal follow-up. The datasets will support internal R&D, model development, and validation efforts, including the advancement of EEG-based digital biomarkers and an AI Co-Scientist platform designed to support neurological and psychiatric clinical studies, especially for pharmaceutical companies and academic hospitals.
Risorius selected OneMedNet based on the strong fit for its R&D requirements. Key differentiators included access to Multi-modal data including high-fidelity EEG and PSG waveforms paired with longitudinal clinical data, substantial data volume to support potential program expansion, a transparent and structured curation process, and a well-organized de-identification workflow. The practical subscription licensing approach enabled Risorius to move quickly from evaluation to execution.
Aaron Green, CEO and President of OneMedNet, stated: “Risorius’ rapid decision to partner with OneMedNet underscores the value of our regulatory-grade neuro data and continuous delivery model. Real-World EEG and PSG waveform data, when paired with longitudinal clinical results, are foundational to the research and development of next-generation solutions focused on solving central nervous system disorders. This agreement reflects growing demand from AI-native companies seeking scalable, high-quality datasets to power digital biomarker development and advanced analytics.”
Sangyoon Bae, CEO of Risorius, added, “We chose OneMedNet because of the clear alignment with our scientific and operational needs. The combination of well-curated EEG and PSG waveform data, meaningful longitudinal follow-up, and a scalable licensing model provides the foundation we need to accelerate internal R&D, model validation, and development of our AI Co-Scientist platform. As we are speeding up on our database construction and R&D projects, we anticipate that this partnership will contribute to our technological competiveness.”
The partnership highlights continued momentum in OneMedNet’s data licensing strategy, our breadth and depth of available data and sales expansion within the high-growth neuro and CNS vertical. The efficient commercial execution demonstrated by rapid contract conversion indicates OneMedNet is positioned as a trusted infrastructure partner enabling AI innovation.
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information. Learn more at www.onemednet.com.
About Risorius
Risorius is a neurotechnology AI company, with the vision of innovation and optimization of the psychiatric and neurologic field. By building EEG-based digital biomarkers and AI-powered research platforms to advance central nervous system innovation across neurology, psychiatry, and sleep, Risorius develops scalable pipelines for signal processing, quality control, and multimodal analytics. This enables biomarker discovery, treatment response modeling, and evidence generation from real-world clinical data.
Risorius is also developing an AI Co-Scientist platform that helps research teams optimize analysis workflows regarding CNS and accelerate hypothesis testing and clinical studies. By translating EEG signal data into actionable insights, Risorius aims to support faster, more data-driven decision-making for CNS research and care delivery.
Learn more at www.risorius.kr
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our products, plans and strategies, and our ability to achieve our operational strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: michael.wong@onemednet.com
Risorius Contacts:
YongKeun Song, COO
Email: yksong16@risorius.kr
SOURCE: ONEMEDNET CORPORATION
FAQ**
How does the strategic data licensing agreement between OneMedNet Corp ONMD and Risorius enhance the potential for developing digital biomarkers for CNS disorders?
What are the expected financial impacts of the licensing agreement between OneMedNet Corp ONMD and Risorius on their recurring revenue streams?
Can you elaborate on the key differentiators that led Risorius to select OneMedNet Corp ONMD as its data partner for neurotechnology advancements?
How does OneMedNet Corp ONMD plan to maintain its competitive edge in the rapidly evolving landscape of AI and Real-World Data in healthcare?
**MWN-AI FAQ is based on asking OpenAI questions about OneMedNet Corp (NASDAQ: ONMD).
NASDAQ: ONMD
ONMD Trading
11.04% G/L:
$0.6838 Last:
587,343 Volume:
$0.6327 Open:
